Carbohydrate deficiency glycoprotein syndrome is the older name for part of a larger group now called congenital disorders of glycosylation, or CDG. In simple words, the body has trouble attaching sugar chains to proteins and fats, and that damages many organs, especially the brain, liver, gut, muscles, hormones, eyes, blood-clotting system, and growth. This is not one single disease with one single cure. Treatment depends on the exact subtype found by genetic testing. For many people, care is mainly supportive, but a few subtypes have targeted treatment such as mannose, D-galactose, manganese, uridine, or pyridoxine. [1][2][3]
Carbohydrate deficiency glycoprotein syndrome is the older name for part of a larger group now called congenital disorders of glycosylation, or CDG. In simple words, the body has trouble attaching sugar chains to proteins and fats, and that damages many organs, especially the brain, liver, gut, muscles, hormones, eyes, blood-clotting system, and growth. This is not one single disease with one single cure. Treatment depends on the exact subtype found by genetic testing. For many people, care is mainly supportive, but a few subtypes have targeted treatment such as mannose, D-galactose, manganese, uridine, or pyridoxine. [1][2][3]
The most important treatment rule is this: first confirm the subtype, because the treatment for MPI-CDG is not the same as the treatment for PGM1-CDG, SLC39A8-CDG, or PMM2-CDG. For example, oral mannose is recommended for MPI-CDG, oral D-galactose helps many patients with PGM1-CDG, and manganese supplementation can help SLC39A8-CDG. In contrast, for common PMM2-CDG, there is still no universal curative medicine, so treatment focuses on seizures, feeding, growth, mobility, clotting, and organ complications. [3][4][5][6][9]
Carbohydrate deficiency glycoprotein syndrome is an older name. Today, doctors usually call it congenital disorders of glycosylation (CDG). This is a group of rare inherited diseases. In these diseases, the body cannot add sugar chains to proteins and fats in the normal way. This sugar-adding process is called glycosylation. Glycosylation is very important because it helps many body proteins work the right way. When this process is broken, the brain, liver, gut, blood, hormones, nerves, muscles, eyes, heart, and growth can all be affected. 1 2
In simple words, this disease means the body makes many important proteins, but those proteins are not “finished” correctly. Because of that, the proteins may be weak, unstable, or unable to do their job. That is why CDG can cause many different problems in one child or adult at the same time. Some people are mildly affected, but others become very sick in infancy. The most common type is PMM2-CDG. 2 3
Most CDG conditions are inherited in an autosomal recessive way. This means the child gets one changed gene from the mother and one changed gene from the father. The parents often look healthy because they carry only one changed copy. The disease starts because a gene change makes one enzyme or transport protein work poorly, and then the glycosylation pathway does not run normally. 4 5
Other Names
Other names for this condition include carbohydrate-deficient glycoprotein syndrome, CDG, CDGS, and congenital disorder of glycosylation. In older papers, some types were named with Roman letters or numbers, such as CDG-Ia, but modern naming usually uses the gene name first, such as PMM2-CDG or MPI-CDG. 1 4 3
Types
- PMM2-CDG – the most common type. It often causes low muscle tone, developmental delay, poor growth, eye misalignment, unusual fat pads, and cerebellar problems. 3 6
- MPI-CDG – often causes liver disease, low blood sugar, gut problems, and protein-losing enteropathy, sometimes with less brain involvement than PMM2-CDG. 7 8
- ALG1-CDG – often causes severe developmental delay, hypotonia, seizures, and multisystem disease. 9 10
- ALG6-CDG – may cause poor growth, seizures, ataxia, and clotting problems. 11 7
- ALG12-CDG – may cause feeding problems, poor growth, and developmental delay. 12
- DOLK-CDG – may cause cardiomyopathy, seizures, skin changes, and developmental delay. 13
- COG5-CDG / COG8-CDG – Golgi-related CDG forms that may cause neurologic and developmental problems. 14 15
- SLC39A8-CDG – may cause developmental delay, low muscle tone, epilepsy, eye problems, and hearing problems. 16
- PGM1-CDG, ATP6V0A2-CDG, TMEM165-CDG, SRD5A3-CDG, DPAGT1-CDG and many others are also recognized. Today, experts describe more than 200 CDG disorders linked to many different genes. 2 17
Causes
1. PMM2 gene change. This is the most common cause of CDG. The PMM2 enzyme helps make a sugar building block needed for normal glycosylation. When PMM2 does not work well, many proteins across the body become poorly glycosylated. 3 18
2. MPI gene change. MPI helps the body use mannose, which is important for glycoprotein building. When MPI is defective, the liver, gut, and blood-clotting systems may be strongly affected. 7 8
3. ALG1 gene change. ALG1 helps early steps of N-linked glycosylation. A harmful change in this gene can lead to severe brain and body symptoms, often starting early in life. 9 10
4. ALG6 gene change. ALG6 also works in early sugar-chain building. Defects can cause poor growth, low muscle tone, seizures, and balance problems. 11 7
5. ALG12 gene change. This gene helps attach sugars in the growing glycan chain. When it is abnormal, feeding trouble and developmental problems may appear in infancy. 12
6. DOLK gene change. DOLK is needed for dolichol kinase activity, which supports glycosylation steps. Defects may especially affect the heart, brain, and skin. 13 2
7. COG5 gene change. COG5 helps protein transport and glycosylation inside the Golgi apparatus. When it fails, neurologic and developmental problems can happen. 14 5
8. COG8 gene change. COG8 defects are another Golgi-related cause. They may lead to cerebellar atrophy, ataxia, and developmental regression. 15
9. SLC39A8 gene change. This gene affects manganese transport and can disturb glycosylation. Problems may include developmental delay, dystonia, epilepsy, and eye disease. 16
10. CCDC115 gene change. This type can strongly affect the liver and may also cause hypotonia and developmental delay. 19
11. SRD5A3 gene change. This gene is part of dolichol-related glycosylation work. Defects can affect the eyes, brain, and development. 5 2
12. DPAGT1 gene change. This gene helps start N-linked glycosylation. Abnormal DPAGT1 can cause developmental disease and may also affect muscles or the neuromuscular junction. 5 20
13. PGM1 gene change. PGM1 defects can cause a mixed disorder with muscle, liver, endocrine, and growth problems because sugar handling and glycosylation are both disturbed. 2 5
14. ATP6V0A2 gene change. This gene affects Golgi function and can cause abnormal glycosylation together with skin and connective tissue findings. 5 17
15. TMEM165 gene change. This is another Golgi-related cause. It can disturb normal processing of proteins and lead to growth and skeletal problems. 2 17
16. SLC35A1 gene change. This transporter gene can cause CDG even when some common screening tests look normal, so diagnosis may be missed if doctors stop too early. 21
17. SLC35A3 gene change. This is another nucleotide-sugar transport defect. It can lead to abnormal glycosylation and developmental disease. 21 17
18. PGM3 gene change. PGM3-related disease can affect glycosylation and may also bring immune system problems. 21 17
19. RFT1 gene change. This gene helps move sugar-linked molecules during N-glycan building. When it is abnormal, severe multisystem disease can happen. 5 17
20. Any inherited defect in the glycosylation pathway. The broad root cause is always a harmful inherited change in a gene that controls sugar-chain building, transport, trimming, or attachment. Experts now recognize around 200 CDG disorders caused by many different gene defects. 17 22
Symptoms
1. Developmental delay. Many children with CDG learn to sit, stand, walk, or speak later than expected because the brain and nerves are affected. 2 3
2. Low muscle tone. Hypotonia means the muscles feel weak or floppy. Babies may feel “soft,” have poor head control, or struggle with movement. 3 9
3. Poor growth or failure to thrive. Some infants do not gain weight or grow as expected because feeding, gut absorption, and body metabolism are affected. 7 12
4. Feeding difficulty. Babies may have poor sucking, vomiting, reflux, or trouble swallowing, which can make nutrition difficult. 2 16
5. Seizures. Some CDG types cause epilepsy. Seizures may start in infancy and can be hard to control in some patients. 9 20
6. Balance and walking problems. Ataxia means poor coordination. A child may walk with a wide base, fall often, or have shaky movements. 3 20
7. Eye problems. Strabismus, nystagmus, poor vision, and other eye findings can occur because the nervous system and eye structures may both be involved. 3 16
8. Intellectual disability or learning problems. Some people have mild learning difficulty, while others have severe cognitive impairment. 2 9
9. Stroke-like episodes. A few CDG types can cause sudden neurologic worsening that looks like stroke, with weakness, sleepiness, or temporary loss of skills. 7 11
10. Liver problems. Some patients have enlarged liver, high liver enzymes, liver failure, or clotting problems related to poor liver function. 7 19
11. Blood-clotting problems. Glycosylation defects can change coagulation proteins, so bleeding or abnormal clotting can happen. 7 8
12. Low blood sugar. Hypoglycemia is seen especially in some types such as MPI-CDG. It can cause sweating, sleepiness, shakiness, or seizures. 1 8
13. Abnormal fat pads or inverted nipples. These body signs are especially known in PMM2-CDG and can help doctors suspect the diagnosis. 3 6
14. Heart disease. Some types, such as DOLK-CDG, may cause cardiomyopathy, which means the heart muscle becomes weak or enlarged. 13
15. Nerve problems. Peripheral neuropathy can cause weakness, reduced reflexes, sensory loss, or walking difficulty in some CDG types. 20 15
Diagnostic Tests
Growth measurement. The doctor checks weight, length or height, and head size. Poor growth, microcephaly, or failure to thrive can support suspicion of CDG. 2 7
General neurologic exam. The doctor checks alertness, muscle tone, posture, reflexes, and development. This can show hypotonia, delay, or movement disorder. 3 20
Eye examination. The doctor looks for strabismus, nystagmus, poor tracking, or other eye signs. Eye findings are common in several CDG forms. 3 16
Liver and abdomen exam. The doctor feels for an enlarged liver or spleen and checks for belly swelling. These signs can point to multisystem disease. 7 19
Developmental assessment. This is a hands-on check of sitting, standing, walking, speech, play, and social milestones. It helps show how much the brain and motor system are affected. 2 3
Gait assessment. The child’s walking and balance are watched carefully. This can show ataxia, falls, wide-based gait, or weakness. 3 20
Tone and strength testing. The examiner moves the limbs and checks resistance and muscle power. It helps detect hypotonia, proximal weakness, or neuropathic signs. 20 22
Feeding and swallowing assessment. A clinician watches sucking, chewing, swallowing, and coordination during feeding. This is useful because many patients have oral-motor or swallowing trouble. 2 16
Serum transferrin isoelectric focusing. This is one of the classic screening tests for CDG. It looks at abnormal transferrin glycosylation patterns and helps show whether N-glycosylation is disturbed. 23 24
Transferrin glycoform analysis by mass spectrometry. This test gives a more detailed look at glycosylation changes. It is useful for diagnosis and for sorting different patterns of CDG. 16 25
Capillary zone electrophoresis or HPLC of transferrin. These are other ways to study transferrin glycosylation. They may detect abnormal type I or type II patterns. 16 25
Molecular genetic testing. Gene panel testing, whole-exome sequencing, or targeted sequencing can identify the exact faulty gene. This is often the key test for final diagnosis. 7 21
Enzyme activity testing. In some types, doctors can measure the activity of PMM, MPI, or another enzyme in blood cells or fibroblasts. This helps confirm uncertain genetic findings. 7 3
Liver function tests. AST, ALT, bilirubin, albumin, and related markers help show whether the liver is affected. 7 19
Coagulation profile. PT, aPTT, antithrombin, protein C, protein S, and other clotting studies are useful because CDG can disturb coagulation factors. 7 8
Blood glucose and metabolic tests. Doctors may check glucose, ketones, lactate, and other metabolic markers, especially when low blood sugar or failure to thrive is present. 1 8
EEG. Electroencephalography records brain electrical activity. It is useful when seizures, staring spells, or unexplained episodes are present. 20 9
Nerve conduction study and EMG. These tests check peripheral nerves and muscles. They can help if the patient has weakness, neuropathy, or suspected neuromuscular involvement. 20 15
Brain MRI. MRI may show cerebellar hypoplasia, cerebellar atrophy, cerebral atrophy, or other changes. This is an important test in many neurologic CDG types. 3 20
Echocardiography or abdominal ultrasound. Echo checks the heart for cardiomyopathy or structural disease, while ultrasound looks at the liver, spleen, kidneys, and fluid collections. Doctors choose one or both depending on symptoms. 13 7
Non-Pharmacological Treatments
- Metabolic specialist follow-up is the foundation of care because CDG can affect many organs at the same time. A metabolic team checks growth, liver function, clotting, feeding, and development regularly. 2) Genetic counseling helps families understand inheritance, future pregnancy risk, and testing of relatives. 3) Early intervention services are very important because many children have delay in speech, sitting, walking, and learning. These services work best when started early. [1][3][4]
- Physical therapy helps improve balance, strength, posture, and walking, especially in children with hypotonia, ataxia, or spasticity. 5) Occupational therapy helps hand use, daily skills, sitting support, adaptive equipment, and school function. 6) Speech and language therapy helps both communication and swallowing safety. These therapies do not cure the glycosylation defect, but they improve function by training the nervous system and supporting safe development. [4][14]
- Feeding therapy is often needed because many patients have poor sucking, chewing, swallowing, reflux, or oral motor weakness. 8) High-calorie nutrition planning helps children with failure to thrive. 9) Tube feeding, including nasogastric or gastrostomy feeding, may be needed when oral feeding is unsafe or not enough. This supports growth, hydration, and safer medicine delivery. [4][7][14]
- Swallow assessment and aspiration prevention are important when coughing, choking, recurrent pneumonia, or poor weight gain appear. 11) Constipation care with fluids, fiber when tolerated, toilet routine, and mobility support can reduce pain and feeding refusal. 12) Reflux precautions such as upright positioning after meals and slower feeds can reduce vomiting and aspiration risk. [4][7]
- Hearing care with formal audiology testing and hearing support is needed in subtypes that affect hearing. 14) Eye care with regular ophthalmology review is important for strabismus, cortical visual problems, and other eye complications. 15) Dental care matters because weak muscle tone, feeding problems, and special diets can worsen oral health. These steps protect function and quality of life. [9][14]
- Orthopedic support may include braces, seating systems, standing frames, or mobility devices for scoliosis, joint tightness, or gait problems. 17) Respiratory support may be needed when weak muscles, poor airway clearance, aspiration, or infections occur. 18) Regular liver and clotting monitoring helps catch dangerous complications early, especially in MPI-CDG and PGM1-CDG. [5][6][14]
- Psychology, family support, and school planning are essential because CDG creates long-term care stress and learning needs. 20) Emergency planning is important for seizures, dehydration, hypoglycemia, stroke-like episodes, or bleeding risk. Families should know when to go to the hospital and which medicines the child uses. [4][5][19]
Drug Treatments and Medical Therapies
There are not 20 universally proven FDA-approved drugs that treat all CDG forms directly. The strongest evidence supports a small number of subtype-specific therapies, and most other medicines are used to control symptoms. That is why doctors choose treatment based on the gene result and the person’s symptoms. [3][7][8]
- Oral mannose is the best-known targeted treatment for MPI-CDG. Consensus guidance recommends starting it as soon as diagnosis is made because it can improve diarrhea, protein-losing enteropathy, low blood sugar, growth, and liver-related problems in many patients. The guideline describes dosing around 150 to 170 mg/kg per dose, four to five times daily, but exact dosing must be individualized by a metabolic specialist. [5][8]
- Oral D-galactose is an evidence-based targeted treatment for PGM1-CDG and can improve glycosylation, liver enzymes, some endocrine issues, and parts of muscle disease and coagulation problems. It is one of the clearest examples of precision treatment in CDG, but it is still subtype-specific rather than a universal CDG cure. [6][8]
- Manganese supplementation is a targeted therapy for SLC39A8-CDG, and some reports also support manganese-based correction in related manganese-handling glycosylation defects. Because manganese can be toxic if overused, blood levels and clinical response must be monitored closely by experts. [9][8]
- Uridine is an important targeted treatment for CAD-related CDG, especially when epilepsy and developmental problems are prominent. Published reports describe marked clinical improvement in some patients, but this is again a subtype-specific treatment and should be supervised by a specialist. [8][7]
- Pyridoxine (vitamin B6) has been reported as a possible targeted option in some rare glycosylation-related conditions with epilepsy, but evidence is much smaller than for mannose, galactose, manganese, or uridine. It should not be started as a casual “immune booster.” It is a medical treatment only when the subtype and clinical picture support it. [7][8]
- Levetiracetam is commonly used when CDG causes seizures. It does not fix the glycosylation defect, but it helps control seizure activity. FDA labeling supports its use for certain seizure types, and dosing is individualized by age, weight, kidney function, and seizure pattern. Common side effects include sleepiness, irritability, weakness, and dizziness. [10][4]
- Diazepam nasal spray may be used as a rescue treatment for seizure clusters in selected patients. It acts quickly to calm excessive brain electrical activity, but it can cause sleepiness and breathing risk, especially with sedatives or opioids. Families need clear emergency instructions before use. [12]
- Baclofen is sometimes used for spasticity or painful muscle stiffness in patients with neurologic involvement. It reduces abnormal muscle tone by acting on spinal nerve signaling. Side effects can include sleepiness, weakness, nausea, and withdrawal symptoms if stopped suddenly. [11]
- Ondansetron may be used for severe nausea and vomiting when feeding problems are part of the illness or during acute illness. It blocks 5-HT3 receptors and can reduce vomiting, which may improve hydration and feeding tolerance. Side effects can include constipation, headache, and heart-rhythm concerns in at-risk patients. [13]
- Laxative therapy such as polyethylene glycol is often used for chronic constipation in medically complex children, including those with neurologic and feeding problems. It helps draw water into stool and makes bowel movements easier, reducing pain, poor appetite, and vomiting triggers. This is symptom treatment, not disease correction. [7]
- Acid-suppressing drugs such as proton pump inhibitors or H2 blockers may be used when reflux, esophagitis, or recurrent vomiting is severe. These medicines reduce acid injury and can help comfort and feeding, but long-term use should be reviewed regularly. [7][14]
- Albumin infusion, glucose support, or diuretics may be used during severe acute episodes such as edema, low albumin, or hypoglycemia in some patients. These hospital treatments are supportive and situation-based, especially in complicated infantile phases. [4][5]
- Anticoagulation or clotting-factor support may be required in selected patients with documented thrombosis, severe coagulation imbalance, or around surgery. This must be individualized because some CDG patients can have both bleeding and clotting risk. [6][19]
- Hormone replacement or endocrine treatment may be needed in subtypes that affect thyroid, glucose control, puberty, or other hormone systems. The exact medicine depends on the endocrine problem, not on CDG alone. [6][7]
- Antibiotics are used only when there is a proven infection. They are not a routine CDG medicine, but they are important when aspiration, weak nutrition, or hospital admissions increase infection risk. [4][14]
There is no standard evidence-based list of six “immunity booster, regenerative, or stem cell drugs” for CDG. At present, these are not established standard care for most patients, and routine use cannot be recommended honestly. Research is moving toward gene-based and molecular therapies, but most remain investigational rather than proven everyday treatment. [8][20]
Dietary and Molecular Supplements
- Mannose may act like a medical nutrition therapy in MPI-CDG by supplying substrate for glycosylation.
- D-galactose may improve glycosylation in PGM1-CDG and some related disorders.
- Manganese may correct manganese-dependent enzyme problems in SLC39A8-CDG, but needs strict monitoring.
- Uridine helps selected CAD-related disease by restoring pyrimidine supply.
- Pyridoxine may help selected seizure-related glycosylation disorders. [5][6][7][9]
- Vitamin D, 7) calcium, 8) iron, 9) multivitamin support, and 10) protein-energy supplements may be needed when poor intake, tube feeding, low mobility, or chronic illness causes nutritional gaps. These do not repair glycosylation itself, but they support bone health, blood production, growth, and general resilience. The exact dose should come from the clinical team after labs and diet review. [7][14]
Procedures and Surgeries
- Gastrostomy tube placement may be done when long-term feeding is unsafe or not enough by mouth.
- Fundoplication may be considered in selected patients with severe reflux and aspiration despite medical treatment.
- Orthopedic surgery can be needed for severe contractures, hip problems, or scoliosis when braces and therapy are not enough.
- Strabismus surgery may help selected eye alignment problems.
- Liver transplantation has been reported in severe, carefully selected cases such as complicated MPI-CDG with progressive liver disease, but it is not routine treatment for all CDG. [3][5][14]
Prevention
CDG is genetic, so the disorder itself usually cannot be prevented after conception, but complications can often be reduced. Helpful prevention steps include: early genetic diagnosis; regular metabolic follow-up; keeping vaccines up to date; avoiding dehydration; treating constipation early; watching for low blood sugar; monitoring clotting before surgery; preventing aspiration during feeding; starting therapy early; and using emergency plans for seizures or sudden neurologic change. [1][4][5]
When to See a Doctor Urgently
Seek urgent medical care for seizures lasting too long, repeated seizure clusters, sudden weakness, unusual sleepiness, blue color, trouble breathing, severe vomiting, dehydration, poor feeding, swelling, black stool, bleeding, jaundice, severe constipation, low blood sugar symptoms, or sudden neurologic change that may suggest a stroke-like episode. In infants, poor weight gain, floppy tone, repeated infections, and developmental delay should prompt specialist review. [4][5][19]
What to Eat and What to Avoid
Good choices usually include regular balanced meals, enough protein, enough calories for growth, safe textures based on swallowing ability, hydration, and any subtype-specific medical nutrition the metabolic team prescribes. Some subtypes benefit from frequent feeds or specialist carbohydrate planning. Avoid food plans copied from the internet, unnecessary fasting, dehydration, very restrictive diets without medical advice, and unproven “immune booster” products marketed for rare disease. For children with aspiration risk, texture and feeding speed matter as much as food choice. [7][6]
Frequently Asked Questions
1. Is this disease curable? Usually no, but some subtypes have targeted treatment that improves symptoms. [3][8]
2. Is it the same as PMM2-CDG? No. PMM2-CDG is only one subtype, though it is a common one. [4]
3. Does every patient need mannose? No. Mannose is mainly for MPI-CDG, not for every CDG. [5]
4. Does every patient need galactose? No. D-galactose is best supported in PGM1-CDG and some selected related disorders. [6][8]
5. Are stem cell drugs standard treatment? No. They are not established standard care for most CDG patients. [8][20]
6. Can CDG cause seizures? Yes. Many subtypes can affect the brain and cause epilepsy or seizure-like episodes. [4][9]
7. Can CDG affect the liver? Yes. Some subtypes have serious liver and clotting problems. [5][6]
8. Can CDG affect feeding and growth? Yes. Feeding difficulty and failure to thrive are common. [1][14]
9. Can adults have CDG? Yes. Some people survive into adulthood and may have stable disability or milder forms. [4]
10. Is physical therapy useful? Yes. It improves function even though it does not repair the gene defect. [4][14]
11. Does a feeding tube mean the child can never eat by mouth? Not always. Some children can still use safe oral feeding depending on swallow risk. [4]
12. Are all supplements safe? No. Even manganese or vitamin products can be harmful if used incorrectly. [7][9]
13. Why is genetic testing so important? Because treatment depends on the exact subtype. [1][3]
14. Can CDG cause bleeding or clotting? Yes. Some patients can have either or both risks. [6][19]
15. What is the best next step after diagnosis? Build a care team with metabolic, neurology, nutrition, therapy, and genetics support, then start subtype-specific treatment if available. [3][14]
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: March 31, 2025.
